WCLC 2023 | Consolidation therapy for unresectable stage III EGFR-mutant NSCLC

Amin Nassar, MD, Yale Cancer Centre, New Haven, CT, outlines the rationale behind a retrospective analysis on consolidation therapy for unresectable stage III EGFR-mutant non-small cell lung cancer (NSCLC). The current standard of care for this patient subset is concurrent chemoradiation followed by consolidation durvalumab. Patients with EGFR-mutant NSCLC treated with consolidation durvalumab demonstrated a lower response rate compared EGFR-wild type tumours. The current treatment paradigm for this patient population is yet to be established. Dr Nassar shares that the retrospective analysis is necessary for addressing the unmet need of effective consolidation therapy for unresectable stage III EGFR-mutant NSCLC. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.